{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:51:27Z","timestamp":1792097487134,"version":"4.4.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,8,16]],"date-time":"2018-08-16T00:00:00Z","timestamp":1534377600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,8,16]],"date-time":"2018-08-16T00:00:00Z","timestamp":1534377600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["091593\/Z\/10\/Z"],"award-info":[{"award-number":["091593\/Z\/10\/Z"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Valproate is an anticonvulsant drug with strong preclinical evidence for reducing anxiety behaviour in rodents but no clear clinical evidence. To motivate clinical trials, we here investigate the use of valproate in a translational human model of anxiety behaviour. In a double-blind, randomised, placebo-controlled trial, <jats:italic>n<\/jats:italic>\u2009=\u2009118 healthy participants played a previously validated approach\/avoidance conflict computer game to measure anxiety-like behaviour, while under 400\u2009mg valproate, under 200\u2009mg of the established anxiolytic\/anticonvulsant pregabalin, or under placebo. Saccadic peak velocity and subjective ratings were assessed to control for drug-induced sedation. Compared to placebo, valproate and pregabaline were anxiolytic in the primary outcome, and several secondary outcomes. Bayesian model comparison decisively demonstrated no differences between the two drugs. Subjective and objective sedation was significantly more pronounced under pregabalin than valproate, but did not explain anxiolytic effects. We demonstrate acute anxiolytic properties of valproate in healthy humans. Both drugs have similar anxiolytic properties at the doses used. Valproate is less sedative than pregabalin. Our results suggest clinical trials on the use of valproate in anxiolytic treatment. More generally, we propose a strategy of screening drugs in human preclinical models that can directly be compared across species, such as the approach\/avoidance conflict computer game used here. This approach could thus facilitate translational anxiety research.<\/jats:p>","DOI":"10.1038\/s41398-018-0206-7","type":"journal-article","created":{"date-parts":[[2018,8,16]],"date-time":"2018-08-16T10:35:12Z","timestamp":1534415712000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Effect of valproate and pregabalin on human anxiety-like behaviour in a randomised controlled trial"],"prefix":"10.1038","volume":"8","author":[{"given":"Dominik R.","family":"Bach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph W.","family":"Korn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Vunder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Bantel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,8,16]]},"reference":[{"key":"206_CR1","unstructured":"Gray, J. A. & McNaughton, N. The Neuropsychology of Anxiety: An Enquiry into the Functions of the Septohippocampal System, Vol. 2 (Oxford University Press, Oxford, 2000)."},{"key":"206_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.yebeh.2011.03.011","volume":"21","author":"KR Kaufman","year":"2011","unstructured":"Kaufman, K. R. Antiepileptic drugs in the treatment of psychiatric disorders. Epilepsy Behav. 21, 1\u201311 (2011).","journal-title":"Epilepsy Behav."},{"key":"206_CR3","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1016\/j.neubiorev.2012.09.001","volume":"37","author":"J Haller","year":"2013","unstructured":"Haller, J., Aliczki, M. & Gyimesine Pelczer, K. Classical and novel approaches to the preclinical testing of anxiolytics: a critical evaluation. Neurosci. Biobehav. Rev. 37, 2318\u20132330 (2013).","journal-title":"Neurosci. Biobehav. Rev."},{"key":"206_CR4","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/nrd4075","volume":"12","author":"G Griebel","year":"2013","unstructured":"Griebel, G. & Holmes, A. 50 years of hurdles and hope in anxiolytic drug discovery. Nat. Rev. Drug Discov. 12, 667\u2013687 (2013).","journal-title":"Nat. Rev. Drug Discov."},{"key":"206_CR5","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S2215-0366(15)00361-2","volume":"3","author":"KE Stephan","year":"2016","unstructured":"Stephan, K. E. et al. Charting the landscape of priority problems in psychiatry, part 1: classification and diagnosis. Lancet Psychiatry 3, 77\u201383 (2016).","journal-title":"Lancet Psychiatry"},{"key":"206_CR6","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/7854_2015_5004","volume":"28","author":"A Der-Avakian","year":"2016","unstructured":"Der-Avakian, A., Barnes, S. A., Markou, A. & Pizzagalli, D. A. Translational assessment of reward and motivational deficits in psychiatric disorders. Curr. Top. Behav. Neurosci. 28, 231\u2013262 (2016).","journal-title":"Curr. Top. Behav. Neurosci."},{"key":"206_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/sj.bjp.0703794","volume":"132","author":"MJ Field","year":"2001","unstructured":"Field, M. J., Oles, R. J. & Singh, L. Pregabalin may represent a novel class of anxiolytic agents with a broad spectrum of activity. Br. J. Pharmacol. 132, 1\u20134 (2001).","journal-title":"Br. J. Pharmacol."},{"key":"206_CR8","first-page":"240","volume":"23","author":"DE Feltner","year":"2003","unstructured":"Feltner, D. E. et al. A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder. J. Clin. Psychopharmacol. 23, 240\u2013249 (2003).","journal-title":"J. Clin. Psychopharmacol."},{"key":"206_CR9","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1176\/appi.ajp.160.3.533","volume":"160","author":"AC Pande","year":"2003","unstructured":"Pande, A. C. et al. Pregabalin in generalized anxiety disorder: a placebo-controlled trial. Am. J. Psychiatry 160, 533\u2013540 (2003).","journal-title":"Am. J. Psychiatry"},{"key":"206_CR10","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1097\/01.jcp.0000155820.74832.b0","volume":"25","author":"RB Pohl","year":"2005","unstructured":"Pohl, R. B., Feltner, D. E., Fieve, R. R. & Pande, A. C. Efficacy of pregabalin in the treatment of generalized anxiety disorder: double-blind, placebo-controlled comparison of BID versus TID dosing. J. Clin. Psychopharmacol. 25, 151\u2013158 (2005).","journal-title":"J. Clin. Psychopharmacol."},{"key":"206_CR11","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1001\/archpsyc.62.9.1022","volume":"62","author":"K Rickels","year":"2005","unstructured":"Rickels, K. et al. Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Arch. Gen. Psychiatry 62, 1022\u20131030 (2005).","journal-title":"Arch. Gen. Psychiatry"},{"key":"206_CR12","doi-asserted-by":"publisher","first-page":"771","DOI":"10.4088\/JCP.v67n0511","volume":"67","author":"SA Montgomery","year":"2006","unstructured":"Montgomery, S. A., Tobias, K., Zornberg, G. L., Kasper, S. & Pande, A. C. Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine. J. Clin. Psychiatry 67, 771\u2013782 (2006).","journal-title":"J. Clin. Psychiatry"},{"key":"206_CR13","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1097\/YIC.0b013e3282f0f0d7","volume":"23","author":"D Feltner","year":"2008","unstructured":"Feltner, D. et al. Long-term efficacy of pregabalin in generalized anxiety disorder. Int. Clin. Psychopharmacol. 23, 18\u201328 (2008).","journal-title":"Int. Clin. Psychopharmacol."},{"key":"206_CR14","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1192\/bjp.bp.107.037788","volume":"193","author":"S Montgomery","year":"2008","unstructured":"Montgomery, S., Chatamra, K., Pauer, L., Whalen, E. & Baldinetti, F. Efficacy and safety of pregabalin in elderly people with generalised anxiety disorder. Br. J. Psychiatry 193, 389\u2013394 (2008).","journal-title":"Br. J. Psychiatry"},{"key":"206_CR15","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1097\/YIC.0b013e32831d7980","volume":"24","author":"S Kasper","year":"2009","unstructured":"Kasper, S. et al. Efficacy of pregabalin and venlafaxine-XR in generalized anxiety disorder: results of a double-blind, placebo-controlled 8-week trial. Int. Clin. Psychopharmacol. 24, 87\u201396 (2009).","journal-title":"Int. Clin. Psychopharmacol."},{"key":"206_CR16","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1097\/YIC.0b013e328350b133","volume":"27","author":"K Rickels","year":"2012","unstructured":"Rickels, K. et al. Adjunctive therapy with pregabalin in generalized anxiety disorder patients with partial response to SSRI or SNRI treatment. Int. Clin. Psychopharmacol. 27, 142\u2013150 (2012).","journal-title":"Int. Clin. Psychopharmacol."},{"key":"206_CR17","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1097\/HRP.0000000000000098","volume":"24","author":"HR Abejuela","year":"2016","unstructured":"Abejuela, H. R. & Osser, D. N. The psychopharmacology algorithm project at the Harvard South Shore Program: an algorithm for generalized anxiety disorder. Harv. Rev. Psychiatry 24, 243\u2013256 (2016).","journal-title":"Harv. Rev. Psychiatry"},{"key":"206_CR18","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/0028-3908(80)90071-4","volume":"19","author":"H Lal","year":"1980","unstructured":"Lal, H. et al. Evidence that GABA mechanisms mediate the anxiolytic action of benzodiazepines: a study with valproic acid. Neuropharmacology 19, 785\u2013789 (1980).","journal-title":"Neuropharmacology"},{"key":"206_CR19","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/S0024-3205(83)80003-4","volume":"33","author":"M Myslobodsky","year":"1983","unstructured":"Myslobodsky, M., Feldon, J. & Lerner, T. Anticonflict action of sodium valproate. Interaction with convulsant benzodiazepine (Ro 5-3663) and imidazodiazepine (Ro 15-1788). Life Sci. 33, 317\u2013321 (1983).","journal-title":"Life Sci."},{"key":"206_CR20","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/S0091-3057(84)80063-5","volume":"21","author":"SV Vellucci","year":"1984","unstructured":"Vellucci, S. V. & Webster, R. A. The role of GABA in the anticonflict action of sodium valproate and chlordiazepoxide. Pharmacol. Biochem. Behav. 21, 845\u2013851 (1984).","journal-title":"Pharmacol. Biochem. Behav."},{"key":"206_CR21","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/0028-3908(84)90150-3","volume":"23","author":"RA Shephard","year":"1984","unstructured":"Shephard, R. A. & Estall, L. B. Effects of chlordiazepoxide and of valproate on hyponeophagia in rats. Evidence for a mutual antagonism between their anxiolytic properties. Neuropharmacology 23, 677\u2013681 (1984).","journal-title":"Neuropharmacology"},{"key":"206_CR22","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1007\/BF00432023","volume":"84","author":"J Simiand","year":"1984","unstructured":"Simiand, J., Keane, P. E. & Morre, M. The staircase test in mice: a simple and efficient procedure for primary screening of anxiolytic agents. Psychopharmacology 84, 48\u201353 (1984).","journal-title":"Psychopharmacology"},{"key":"206_CR23","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/0091-3057(95)00100-B","volume":"52","author":"L de Angelis","year":"1995","unstructured":"de Angelis, L. Effects of valproate and lorazepam on experimental anxiety: tolerance, withdrawal, and role of clonidine. Pharmacol. Biochem. Behav. 52, 329\u2013333 (1995).","journal-title":"Pharmacol. Biochem. Behav."},{"key":"206_CR24","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1007\/s002130050148","volume":"128","author":"A Dalvi","year":"1996","unstructured":"Dalvi, A. & Rodgers, R. J. GABAergic influences on plus-maze behaviour in mice. Psychopharmacology 128, 380\u2013397 (1996).","journal-title":"Psychopharmacology"},{"key":"206_CR25","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/S0091-3057(00)00408-1","volume":"68","author":"A Dalvi","year":"2001","unstructured":"Dalvi, A. & Rodgers, R. J. Anxiolytic effects of valproate and diazepam in mice are differentially sensitive to picrotoxin antagonism. Pharmacol. Biochem. Behav. 68, 23\u201332 (2001).","journal-title":"Pharmacol. Biochem. Behav."},{"key":"206_CR26","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1358\/mf.2003.25.4.769674","volume":"25","author":"AP Lang","year":"2003","unstructured":"Lang, A. P. & de Angelis, L. Experimental anxiety and antiepileptics: the effects of valproate and vigabatrin in the mirrored chamber test. Methods Find. Exp. Clin. Pharmacol. 25, 265\u2013271 (2003).","journal-title":"Methods Find. Exp. Clin. Pharmacol."},{"key":"206_CR27","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1177\/070674379804300109","volume":"43","author":"M Baetz","year":"1998","unstructured":"Baetz, M. & Bowen, R. C. Efficacy of divalproex sodium in patients with panic disorder and mood instability who have not responded to conventional therapy. Can. J. Psychiatry 43, 73\u201377 (1998).","journal-title":"Can. J. Psychiatry"},{"key":"206_CR28","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.jad.2012.07.016","volume":"145","author":"DV Sheehan","year":"2013","unstructured":"Sheehan, D. V. et al. Randomized, placebo-controlled trial of quetiapine XR and divalproex ER monotherapies in the treatment of the anxious bipolar patient. J. Affect Disord. 145, 83\u201394 (2013).","journal-title":"J. Affect Disord."},{"key":"206_CR29","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s00406-010-0109-y","volume":"260","author":"G Perugi","year":"2010","unstructured":"Perugi, G. et al. Adjunctive valproate in panic disorder patients with comorbid bipolar disorder or otherwise resistant to standard antidepressants: a 3-year \u201copen\u201d follow-up study. Eur. Arch. Psychiatry Clin. Neurosci. 260, 553\u2013560 (2010).","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"206_CR30","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.eurpsy.2007.08.001","volume":"23","author":"NA Aliyev","year":"2008","unstructured":"Aliyev, N. A. & Aliyev, Z. N. Valproate (depakine-chrono) in the acute treatment of outpatients with generalized anxiety disorder without psychiatric comorbidity: randomized, double-blind placebo-controlled study. Eur. Psychiatry 23, 109\u2013114 (2008).","journal-title":"Eur. Psychiatry"},{"key":"206_CR31","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.cub.2014.01.046","volume":"24","author":"DR Bach","year":"2014","unstructured":"Bach, D. R. et al. Human hippocampus arbitrates approach-avoidance conflict. Curr. Biol. 24, 541\u2013547 (2014).","journal-title":"Curr. Biol."},{"key":"206_CR32","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1038\/nn.4101","volume":"18","author":"GG Calhoon","year":"2015","unstructured":"Calhoon, G. G. & Tye, K. M. Resolving the neural circuits of anxiety. Nat. Neurosci. 18, 1394\u20131404 (2015).","journal-title":"Nat. Neurosci."},{"key":"206_CR33","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1176\/appi.ajp.2010.09091379","volume":"167","author":"T Insel","year":"2010","unstructured":"Insel, T. et al. Research domain criteria (RDoC): toward a new classification framework for research on mental disorders. Am. J. Psychiatry 167, 748\u2013751 (2010).","journal-title":"Am. J. Psychiatry"},{"key":"206_CR34","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.biopsych.2017.01.018","volume":"82","author":"CW Korn","year":"2017","unstructured":"Korn, C. W. et al. Amygdala lesions reduce anxiety-like behavior in a human benzodiazepine-sensitive approach avoidance conflict test.Biol. Psychiatry 82, 522\u2013531 (2017).","journal-title":"Biol. Psychiatry"},{"key":"206_CR35","doi-asserted-by":"publisher","first-page":"175","DOI":"10.3758\/BF03193146","volume":"39","author":"F Faul","year":"2007","unstructured":"Faul, F., Erdfelder, E., Lang, A. G. & Buchner, A. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav. Res. Methods 39, 175\u2013191 (2007).","journal-title":"Behav. Res. Methods"},{"key":"206_CR36","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3389\/fnhum.2012.00042","volume":"6","author":"RL Aupperle","year":"2012","unstructured":"Aupperle, R. L. et al. Pregabalin effects on neural response to emotional faces. Front. Human Neurosci. 6, 42 (2012).","journal-title":"Front. Human Neurosci."},{"key":"206_CR37","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1038\/npp.2011.32","volume":"36","author":"RL Aupperle","year":"2011","unstructured":"Aupperle, R. L. et al. Pregabalin influences insula and amygdala activation during anticipation of emotional images. Neuropsychopharmacology 36, 1466\u20131477 (2011).","journal-title":"Neuropsychopharmacology"},{"key":"206_CR38","unstructured":"Laux, L., Glanzmann, P., Schaffner, P. & Spielberger, C. D. Das State-Trait-Angstinventar (Beltz, Weinheim, 1981)."},{"key":"206_CR39","unstructured":"Hautzinger, M., Bailer, M., Worall, H. & Keller, F. Beck-Depressions-Inventar (Hans Huber, Bern, 1994)."},{"key":"206_CR40","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1046\/j.1365-2125.2002.t01-10-01714.x","volume":"55","author":"SJ de Visser","year":"2003","unstructured":"de Visser, S. J. et al. Biomarkers for the effects of benzodiazepines in healthy volunteers. Br. J. Clin. Pharmacol. 55, 39\u201350 (2003).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"206_CR41","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.bandc.2008.08.026","volume":"68","author":"JL Reilly","year":"2008","unstructured":"Reilly, J. L., Lencer, R., Bishop, J. R., Keedy, S. & Sweeney, J. A. Pharmacological treatment effects on eye movement control. Brain Cogn. 68, 415\u2013435 (2008).","journal-title":"Brain Cogn."},{"key":"206_CR42","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/S0166-4328(99)00152-7","volume":"108","author":"GS Masson","year":"2000","unstructured":"Masson, G. S. et al. Lorazepam-induced modifications of saccadic and smooth-pursuit eye movements in humans: attentional and motor factors. Behav. Brain Res. 108, 169\u2013180 (2000).","journal-title":"Behav. Brain Res."},{"key":"206_CR43","doi-asserted-by":"publisher","first-page":"111","DOI":"10.2307\/271063","volume":"25","author":"AE Raftery","year":"1995","unstructured":"Raftery, A. E. Bayesian model selection in social research. Sociol. Methodol. 25, 111\u2013163 (1995).","journal-title":"Sociol. Methodol."},{"key":"206_CR44","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.biopsych.2015.12.016","volume":"80","author":"N Walz","year":"2016","unstructured":"Walz, N., Muhlberger, A. & Pauli, P. A human open field test reveals thigmotaxis related to agoraphobic fear. Biol. Psychiatry 80, 390\u2013397 (2016).","journal-title":"Biol. Psychiatry"},{"key":"206_CR45","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1004646","volume":"11","author":"DR Bach","year":"2015","unstructured":"Bach, D. R. Anxiety-like behavioural inhibition is normative under environmental threat-reward correlations. PLoS Comput. Biol. 11, e1004646 (2015).","journal-title":"PLoS Comput. Biol."},{"key":"206_CR46","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1037\/xhp0000282","volume":"43","author":"DR Bach","year":"2017","unstructured":"Bach, D. R. The cognitive architecture of anxiety-like behavioral inhibition. J. Exp. Psychol. Hum. Percept. Perform. 43, 18\u201329 (2017).","journal-title":"J. Exp. Psychol. Hum. Percept. Perform."},{"key":"206_CR47","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1590\/S0100-879X2003000400003","volume":"36","author":"FG Graeff","year":"2003","unstructured":"Graeff, F. G., Parente, A., Del-Ben, C. M. & Guimaraes, F. S. Pharmacology of human experimental anxiety. Braz. J. Med. Biol. Res. 36, 421\u2013432 (2003).","journal-title":"Braz. J. Med. Biol. Res."},{"key":"206_CR48","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.brat.2017.04.010","volume":"96","author":"N Kirlic","year":"2017","unstructured":"Kirlic, N., Young, J. & Aupperle, R. L. Animal to human translational paradigms relevant for approach avoidance conflict decision making. Behav. Res. Ther. 96, 14\u201329 (2017).","journal-title":"Behav. Res. Ther."},{"key":"206_CR49","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.neuroimage.2016.04.070","volume":"136","author":"MW Schlund","year":"2016","unstructured":"Schlund, M. W. et al. The tipping point: value differences and parallel dorsalventral frontal circuits gating human approach-avoidance behavior.Neuroimage 136, 94\u2013105 (2016).","journal-title":"Neuroimage"},{"key":"206_CR50","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.bbr.2011.08.003","volume":"225","author":"RL Aupperle","year":"2011","unstructured":"Aupperle, R. L., Sullivan, S., Melrose, A. J., Paulus, M. P. & Stein, M. B. A reverse translational approach to quantify approach-avoidance conflict in humans. Behav. Brain Res. 225, 455\u2013463 (2011).","journal-title":"Behav. Brain Res."},{"key":"206_CR51","first-page":"165","volume":"11","author":"P Nuss","year":"2015","unstructured":"Nuss, P. Anxiety disorders and GABA neurotransmission: a disturbance of modulation. Neuropsychiatr. Dis. Treat. 11, 165\u2013175 (2015).","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"206_CR52","first-page":"133","volume":"37","author":"CB Nemeroff","year":"2003","unstructured":"Nemeroff, C. B. The role of GABA in the pathophysiology and treatment of anxiety disorders. Psychopharmacol. Bull. 37, 133\u2013146 (2003).","journal-title":"Psychopharmacol. Bull."},{"key":"206_CR53","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1124\/jpet.111.180976","volume":"338","author":"SM Lotarski","year":"2011","unstructured":"Lotarski, S. M. et al. Anxiolytic-like activity of pregabalin in the Vogel conflict test in alpha2delta-1 (R217A) and alpha2delta-2 (R279A) mouse mutants. J. Pharmacol. Exp. Ther. 338, 615\u2013621 (2011).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"206_CR54","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/S0197-0186(00)00013-9","volume":"37","author":"CU Johannessen","year":"2000","unstructured":"Johannessen, C. U. Mechanisms of action of valproate: a commentatory. Neurochem. Int. 37, 103\u2013110 (2000).","journal-title":"Neurochem. Int."},{"key":"206_CR55","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.1007\/s00018-007-7079-x","volume":"64","author":"G Rosenberg","year":"2007","unstructured":"Rosenberg, G. The mechanisms of action of valproate in neuropsychiatric disorders: can we see the forest for the trees? Cell Mol. Life Sci. 64, 2090\u20132103 (2007).","journal-title":"Cell Mol. Life Sci."},{"key":"206_CR56","doi-asserted-by":"publisher","first-page":"756","DOI":"10.4088\/JCP.v63n0901","volume":"63","author":"SM Stahl","year":"2002","unstructured":"Stahl, S. M. Don\u2019t ask, don\u2019t tell, but benzodiazepines are still the leading treatments for anxiety disorder. J. Clin. Psychiatry 63, 756\u2013757 (2002).","journal-title":"J. Clin. Psychiatry"},{"key":"206_CR57","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1097\/01.jcp.0000155821.74832.f9","volume":"25","author":"K Mitte","year":"2005","unstructured":"Mitte, K., Noack, P., Steil, R. & Hautzinger, M. A meta-analytic review of the efficacy of drug treatment in generalized anxiety disorder. J. Clin. Psychopharmacol. 25, 141\u2013150 (2005).","journal-title":"J. Clin. Psychopharmacol."},{"key":"206_CR58","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1097\/YIC.0000000000000144","volume":"32","author":"SA Montgomery","year":"2017","unstructured":"Montgomery, S. A., Lyndon, G., Almas, M., Whalen, E. & Prieto, R. Early improvement with pregabalin predicts endpoint response in patients with generalized anxiety disorder: an integrated and predictive data analysis. Int. Clin. Psychopharmacol. 32, 41\u201348 (2017).","journal-title":"Int. Clin. Psychopharmacol."}],"container-title":["Translational Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41398-018-0206-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-018-0206-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-018-0206-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T11:26:34Z","timestamp":1671535594000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41398-018-0206-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,16]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["206"],"URL":"https:\/\/doi.org\/10.1038\/s41398-018-0206-7","relation":{},"ISSN":["2158-3188"],"issn-type":[{"value":"2158-3188","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,16]]},"assertion":[{"value":"8 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"157"}}